| Project/Area Number |
17591262
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
TAKEHARA Yasuo Hamamatsu University Hospital, MD, associate professor, 医学部附属病院, 助教授 (70188217)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAKAHARA Harumi Hamamatsu University School of Medicine, MD, professor, 医学部, 教授 (10187031)
MURAMATSU Katsuaki Hamamatsu University Hospital, MD, assistant professor, 医学部附属病院, 助手 (40397401)
|
|---|
| Project Period (FY) |
2005 – 2006
|
| Project Status |
Completed (Fiscal Year 2006)
|
| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,600,000)
Fiscal Year 2006: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2005: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | blood pool agent / hepatocellular carcinoma / dendrimer / magnetic resonance imaging / contrast media / tissue specific / 組織特異性 / MRI |
|---|
| Research Abstract |
Animal study was made to test if a newly developed blood pool MR contrast agent dendrimer-core can show better and sustained enhancement of experimentally induced vascular-rich hepatocellular carcinoma as compared to conventional Gd-DTPA contrast enhancement. Twenty-seven vascular-rich hepatocellular carcinoma nodules were chemically induced by administering diethylnitrosamine solution to five F344 rats. Before and after intravenous administration of 0.05 mmol/kg dendrimer-core contrast media, T1 weighted images were acquired either with conventional spin echo sequence (TR/TE;250/9.1) or gradient echo sequence (TR/TE ; 4.5/1.8) on 3.0T MR scanner. Contrast to noise ratio (CNR) and signal intensity ratio were calculated for each nodule before and after contrast enhancement. Gd-DTPA enhanced imaging was also performed as a control study. As a result, stronger (more than 5-fold) and sustained (longer than 2 hours) contrast enhancement was obtained with dendrimer contrast agent. With use of dendrimer-core agent, improved and sustained contrast enhancement is feasible both with gradient echo sequence and conventional spin echo imaging, which may be used for interventional procedure with MRI and a whole liver imaging with lower performance gradient imagers. Recently, numerous potentially anti-angiogenic drugs for cancer therapy are being investigated. This new cancer treatment strategy may require new blood pool contrast agent that may be used for determining the indications of anti-angiogenic drugs or their response after the pharmacological interventions. Our dendrimer core may be one of the candidates for this use.
|
